tesamorelin raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-03-19 and is reviewed periodically as new material appears.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
The peptide is supplied as a lyophilized powder in single-use vials and is normally kept refrigerated between two and eight degrees Celsius, protected from light. Once dissolved, the solution is handled carefully because peptide bonds and the acyl modification can degrade under warm or alkaline conditions. Vials are inspected for cracks, and the powder is checked for color and uniformity before handling. Temperature excursions during shipping are a frequent reason for quality questions.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from truncated or oxidized forms. Mass spectrometry confirms the expected molecular weight, and peptide mapping after enzymatic digestion verifies the amino acid sequence. Water content is measured because residual moisture affects stability, and tests for aggregates or particulates are standard for injectable peptides. Circular dichroism can indicate whether the molecule has adopted an unexpected secondary structure in solution.
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
The company's first customers were educational institutions and life-sciences companies that were building supercomputers for purposes of drug discovery, computational fluid dynamics, genetic and genomic research, to predict response to drugs, and for COVID-19 research. Early customers included GlaxoSmithKline, AstraZeneca, the National Energy Technology Laboratory, Lawrence Livermore National Laboratory, the Pittsburgh Supercomputing Center, and Edinburgh Parallel Computing Centre. In September 2020, the company opened an office in Japan and partnered with Tokyo Electron. In April 2021, the company released its CS-2 system, based on the company's Wafer Scale Engine Two (WSE-2), which has 850,000 cores. The CS-2 is manufactured by the 7 nm process of TSMC. It is 26 inches (660 mm) tall and fits in one-third of a standard data center rack. The WSE-2 has 850,000 cores and 2.6 trillion transistors. It enables a single system to support AI models with more than 120 trillion parameters. The WSE-2 expanded on-chip SRAM to 40 gigabytes, memory bandwidth to 20 petabytes per second, and total fabric bandwidth to 220 petabits per second. Customers included TotalEnergies, nference, the National Center for Supercomputing Applications (NCSA), and the Leibniz Supercomputing Centre. In August 2021, Cerebras announced a partnership with Peptilogics on the development of AI for peptide therapeutics. In June 2022, Cerebras set a record for the largest AI models ever trained on one device—a single CS-2 system with one Cerebras wafer trained models with up to 20 billion parameters.
genetic redundancy The redundant encoding of two or more distinct gene products that ultimately perform the same biochemical function. Mutations in one of these genes may have a smaller effect on fitness than might be expected, since the redundant genes often compensate for any loss of function and obviate any gain of function.
DNA can be damaged by many sorts of mutagens, which change the DNA sequence. Mutagens include oxidizing agents, alkylating agents and also high-energy electromagnetic radiation such as ultraviolet light and X-rays. The type of DNA damage produced depends on the type of mutagen. For example, UV light can damage DNA by producing thymine dimers, which are cross-links between pyrimidine bases. On the other hand, oxidants such as free radicals or hydrogen peroxide produce multiple forms of damage, including base modifications, particularly of guanosine, and double-strand breaks. A typical human cell contains about 150,000 bases that have suffered oxidative damage. Of these oxidative lesions, the most dangerous are double-strand breaks, as these are difficult to repair and can produce point mutations, insertions, deletions from the DNA sequence, and chromosomal translocations. These mutations can cause cancer. Because of inherent limits in the DNA repair mechanisms, if humans lived long enough, they would all eventually develop cancer. DNA damages that are naturally occurring, due to normal cellular processes that produce reactive oxygen species, the hydrolytic activities of cellular water, etc., also occur frequently. Although most of these damages are repaired, in any cell some DNA damage may remain despite the action of repair processes. These remaining DNA damages accumulate with age in mammalian postmitotic tissues. This accumulation appears to be an important underlying cause of aging.
==== Economic reform ==== Libya's economy witnessed increasing privatization; although rejecting the socialist policies of nationalized industry advocated in The Green Book, government figures asserted that they were forging "people's socialism" rather than capitalism. Gaddafi welcomed these reforms, calling for wide-scale privatization in a March 2003 speech; he promised that Libya would join the World Trade Organization. These reforms encouraged private investment in Libya's economy. By 2004, there was US$40 billion of direct foreign investment in Libya, a six-fold rise over 2003. Sectors of Libya's population reacted against these reforms with public demonstrations, and in March 2006, revolutionary hard-liners took control of the GPC cabinet; although scaling back the pace of the changes, they did not halt them. In 2010, plans were announced that would have seen half the Libyan economy privatized over the next decade, these plans appear to have been soon abandoned however, as the companies that the government stated they were going to float on the stock market, among them the National Commercial Bank and the Libyan Iron and Steel Company were never floated and remained 100% state-owned. Many socialist policies remained however, with subsidiaries of logistics company HB Group being nationalized in 2007. Agriculture remained largely untouched by the reforms, with farms remaining cooperatives, the Agricultural Bank of Libya remaining wholly state-owned and state interventionist policies and price controls remaining.
=== Pharmacodynamics === Ramelteon is a melatonin receptor agonist with both high affinity for melatonin MT1 and MT2 receptors and selectivity over the non-human MT3 receptor. Ramelteon demonstrates full agonist activity in vitro in cells expressing human MT1 or MT2 receptors, and high selectivity for human MT1 and MT2 receptors compared to the non-human MT3 receptor. The affinity of ramelteon for the MT1 and MT2 receptors is 3 to 16 times higher than that of melatonin. Ramelteon has 8-fold higher affinity for the MT1 receptor over the MT2 receptor. The binding profile of ramelteon distinguishes it from melatonin, tasimelteon, and agomelatine. Remelteon has a clinically irrelevant affinity for the serotonin 5-HT1A receptor (Ki = 5.6 μM). The major metabolite of ramelteon, M-II, is active and has approximately one-tenth and one-fifth the binding affinity of the parent molecule for the human MT1 and MT2 receptors, respectively, and is 17- to 25-fold less potent than ramelteon in in vitro functional assays. Although the potency of M-II at MT1 and MT2 receptors is lower than the parent drug, M-II circulates at higher concentrations than the parent producing 20- to 100-fold greater mean systemic exposure when compared to ramelteon. M-II has weak affinity for the serotonin 5-HT2B receptor, but no appreciable affinity for other receptors or enzymes. Similar to ramelteon, M-II does not interfere with the activity of a number of endogenous enzymes.
Sources: en.wikipedia.org
Herbal teas or herb teas, technically known as herbal infusions and less commonly called tisanes, are beverages made from the infusion or decoction in water of any herbs, spices, or other plant material (except tea leaves). Many herbs used in teas/tisanes are also used in herbal medicine and in folk medicine. Herbal teas are not technically a tea because they are not brewed from the tea plant (Camellia sinensis). The term "herbal tea" is often used to distinguish these infusions from true teas (e.g., black, green, white, yellow, oolong). Blended teas include material from other plants, such as in jasmine tea, genmaicha, and Earl Grey tea. Unlike true teas, most tisanes do not naturally contain caffeine (though tea can be decaffeinated, i.e., processed to remove caffeine). A number of plants, however, do contain psychoactive compounds, such as caffeine or another stimulant, like theobromine, cocaine or ephedrine. Some have the opposite effect, acting as a sedative. Some common infusions have specific names such as mate (yerba mate) and rooibos (red bush).
The bound sequences are eluted and amplified by PCR to prepare for subsequent rounds of selection in which the stringency of the elution conditions can be increased to identify the tightest-binding sequences. A caution to consider in this method is that the selection of extremely high, sub-nanomolar binding affinity entities may not in fact improve specificity for the target molecule. Off-target binding to related molecules could have significant clinical effects. SELEX has been used to develop a number of aptamers that bind targets interesting for both clinical and research purposes. Nucleotides with chemically modified sugars and bases have been incorporated into SELEX reactions to increase the chemical diversity at each base, expanding the possibilities for specific and sensitive binding, or increasing stability in serum or in vivo.
Mutagenesis experiment: The direct method to investigate the DFE is to induce mutations and then measure the mutational fitness effects, which has already been done in viruses, bacteria, yeast, and Drosophila. For example, most studies of the DFE in viruses used site-directed mutagenesis to create point mutations and measure relative fitness of each mutant. In Escherichia coli, one study used transposon mutagenesis to directly measure the fitness of a random insertion of a derivative of Tn10. In yeast, a combined mutagenesis and deep sequencing approach has been developed to generate high-quality systematic mutant libraries and measure fitness in high throughput. However, given that many mutations have effects too small to be detected and that mutagenesis experiments can detect only mutations of moderately large effect; DNA sequence analysis can provide valuable information about these mutations.
Cosmetics, such as lipstick, recovered from a crime scene may provide valuable forensic information. Lipstick smears left on cigarette butts, glassware, clothing, bedding; napkins, paper, etc. may be valuable evidence. Lipstick recovered from clothing or skin may also indicate physical contact between individuals. Forensic analysis of recovered lipstick smear evidence can provide valuable information on the recent activities of a victim or suspect. Trace elemental analysis of lipstick smears could be used to complement existing visual comparative procedures to determine the lipstick brand and color. Single Particle Inductively Coupled Plasma Mass Spectroscopy (SP ICP-MS) was designed for particle suspensions in 2000 by Claude Degueldre. He first tested this new methodology at the Forel Institute of the University of Geneva and presented this new analytical approach at the 'Colloid 2oo2' symposium during the spring 2002 meeting of the EMRS, and in the proceedings in 2003. This study presents the theory of SP ICP-MS and the results of tests carried out on clay particles (montmorillonite) as well as other suspensions of colloids. This method was then tested on thorium dioxide nanoparticles by Degueldre & Favarger (2004), zirconium dioxide by Degueldre et al (2004) and gold nanoparticles, which are used as a substrate in nanopharmacy, and published by Degueldre et al (2006). Subsequently, the study of uranium dioxide nano- and micro-particles gave rise to a detailed publication, Ref. Degueldre et al (2006). Since 2010 the interest for SP ICP-MS has exploded.
Sources: en.wikipedia.org
Following the contested 2006 presidential election, Felipe Calderón initiated Operation Michoacán, a militarized campaign against drug cartels as an effort to consolidate political authority, strengthen the legitimacy of his administration, and rally public support. Often described as the first major campaign of the conflict, Operation Michoacán marked the beginning of large-scale confrontations between government forces and drug cartels, eventually involving about 45,000 troops together with state and federal police. Calderón's government pioneered a militarized "kingpin strategy" that relied on Mexican Army and Federal Police deployments to capture or kill cartel leaders. This security approach was led by Genaro García Luna (Secretariat of Public Security), Eduardo Medina Mora (Attorney General of Mexico), and Guillermo Galván Galván (Secretariat of National Defense). Early operations included Operation Baja California, Operation Sinaloa, and Operation Chihuahua. Although drug-related violence spiked markedly in contested areas along the U.S. border, such as Ciudad Juárez, Tijuana, and Matamoros, the government was initially successful in detaining and killing high-ranking cartel members, including Alfredo Beltrán Leyva, Arturo Beltrán Leyva, Ignacio Coronel Villarreal, Antonio Cárdenas Guillén, and Vicente Carrillo Leyva. Calderón expressed that the cartels seek "to replace the government" and "are trying to impose a monopoly by force of arms, and are even trying to impose their own laws".
=== Metamorphism === Monazite geochronology is generally regarded as a powerful tool to reveal metamorphic history. Metamorphism is the mineralogical and textural changes in preexisting rocks in response to a change in environment to different temperatures and pressures. It occurs at a temperature above diagenesis (~200 °C) and below melting (>800 °C). The mineral assemblage formed by metamorphism depends on the composition of the parent rock (protolith) and more importantly, the stability of different minerals at varying temperature and pressure (P-T). A set of mineral assemblages that form under similar temperature and pressure is called a metamorphic facies. Most mineral changes during rock burial, uplift, hydrothermal processes and deformation are associated with metamorphic reactions. Monazite is commonly found in many metamorphic rocks, especially in those formed from pelites and sandstones. The zonation in monazite reflects the successive monazite forming events. They may be formed from reactions along a single pressure-temperature (P-T) loop in a phase diagram, or reactions without changing P-T. For a metamorphic event, monazite is formed by the reactions with more than one P-T loop. The objective of monazite geochronology is to relate these monazite forming events/reactions with P-T conditions. We can then put time constrains on the P-T loops, forming a comprehensive pressure-temperature-time loops revealing the metamorphic history of the rocks.
=== Mechanistic Models === Mechanistic models provide a detailed understanding of the underlying biological and physiological processes governing drug behavior. These models offer insights into the mechanisms influencing drug absorption, distribution, metabolism, and elimination, aiding in predicting drug responses in diverse scenarios.
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
It acts on the growth hormone–releasing hormone receptor, a Gs-coupled receptor found on pituitary somatotroph cells. Activation raises cAMP and prompts pulsatile hormone release.